Table 1 Baseline characteristics of the patient population
Patient population n = 64 (100%) | |
|---|---|
Gender | |
Male | 33 (51.6) |
Female | 31 (48.4) |
Age | |
< 60 years | 28 (43.8) |
≥ 60 years | 36 (56.2) |
GNAQ | |
Mutated | 8 (12.5) |
Wildtype | 8 (12.5) |
Unknown | 48 (75.0) |
GNA11 | |
Mutated | 10 (15.6) |
Wildtype | 5 (7.8) |
Unknown | 49 (76.6) |
ECOG status | |
0 | 49 (76.6) |
1 | 11 (17.2) |
2 | 1 (1.6) |
3 | 1 (1.6) |
Unknown | 2 (3.1) |
Serum LDH | |
Normal | 28 (43.8) |
Elevated (>ULN) | 33 (51.6) |
Unknown | 3 (4.7) |
Previous systemic therapies | |
0 | 50 (78.1) |
1 | 12 (18.8) |
≥ 2 | 2 (3.1) |
Previous ipilimumab monotherapy | 2 (3.1) |
Previous PD-1 inhibitor monotherapy | 12 (18.8) |
Liver-directed therapies | |
0 | 33 (51.6) |
1 | 30 (46.9) |
≥ 2 | 1 (1.6) |
Metastatic sitesa | |
Liver | 58 (90.6) |
Lung | 23 (35.9) |
Bone | 17 (26.6) |
Lymph nodes | 12 (18.8) |
CNS | 4 (6.3) |
Treatment regimen | |
Ipilimumab 3 mg/kg + nivolumab 1 mg/kg Q3W, followed by nivolumab 3 mg/kg Q2W | 59 (92.2%) |
Ipilimumab 1 mg/kg + pembrolizumab 2 mg/kg Q3W, followed by pembrolizumab 2 mg/kg Q3W | 5 (7.8%) |